
    
      Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong
      suspicion of neuroblastoma or pheochromocytoma.

      Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of
      I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration
      of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free
      I-123-iodide
    
  